Skip to main content
. Author manuscript; available in PMC: 2013 Jun 3.
Published in final edited form as: Cell Transplant. 2011 Apr 29;20(0):1915–1920. doi: 10.3727/096368911X566253

Table 1.

Tumor formation by hCD47-LCL and pKS-LCL cells in NOD/SCID mice

LCL cell administration (n)1 No. with tumor (time of analysis)2 No. with hCD47-LCL / No. with pKS-LCL3
Peritoneal Cavity (12) 5 (17, 21, 31, 35, 45) 5/0
Kidney capsule (5) 4 (14, 21, 35, 35) 4/0
1

A mixture (1:1) of hCD47-LCL and pKS-LCL cells (total 5×107 cells/mouse) were injected into peritoneal cavity (n=12) or renal subcapsular space (n=5).

2

Number of mice with visible tumor at sacrifice (days after LCL cell administration).

3

Number of mice with hCD47-LCL (human CD47+) and pKS-LCL (human CD47−) tumor cells determined by flow cytometric analysis of tumor cell suspensions using anti-human CD47 mAb.